Other languages Nuvation Bio Inc.

Equities

NUVB

US67080N1019

Real-time Estimate Cboe BZX Other stock markets 11:30:08 2024-07-03 am EDT			5-day change	1st Jan Change
2.975 ^USD	-0.17%		-0.33%	+97.35%

Jun. 24	Nuvation Bio Inc.(NYSE:NUVB) added to S&P Pharmaceuticals Select Industry Index	CI
Jun. 13	Nuvation Bio Insider Bought Shares Worth $500,089, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nuvation Bio Insider Bought Shares Worth $500,089, According to a Recent SEC Filing	Jun. 13
Nuvation Bio Inc. Announces Data from Pivotal Phase 2 Trust-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, Publishes in Journal of Clinical Oncology and Reports at 2024 ASCO Annual Meeting	Jun. 01
Nuvation Bio Q1 Loss Narrows; Shares Fall After Hours	May. 14
Nuvation Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14
Nuvation Bio Closes Acquisition of AnHeart Therapeutics	Apr. 10
Nuvation Bio Inc. Announces Appointment of Directors	Apr. 10
Nuvation Bio Inc. completed the acquisition of AnHeart Therapeutics Ltd	Apr. 08
Nuvation Bio Inc. Appoints Colleen Sjogren as Chief Commercial Officer	Mar. 28
Nuvation Bio Shares Jump After Jefferies Upgrade	Mar. 27
Top Premarket Gainers	Mar. 27
Nuvation Bio Agrees to Acquire AnHeart Therapeutics in All-Stock Deal -- Shares Fall	Mar. 25
Nuvation Bio Doses First Patient in Phase 1/2 Study of Advanced Solid Tumor Treatment	Mar. 14
Nuvation Bio Inc. Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors	Mar. 14
Nuvation Bio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
Nuvation Bio Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29
Nuvation Bio Receives US FDA Clearance for Investigational New Drug Application for NUV-1511	Jan. 08
Nuvation Bio Inc. Announces Appointment of Robert Mashal to Its Board of Directors	Jan. 08
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors	Jan. 08
Nuvation Bio Inc. Announces Resignation of Oleg Nodelman from Board of Directors	Dec. 14
Nuvation Bio Inc. Appoints Moses Makunje as Principal Accounting Officer and Principal Financial Officer	Nov. 27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Nuvation Bio Inc.

Equities

NUVB

US67080N1019

Other languages

Filters